What is NovelCath?
NovelCath, operating as part of Cirtec Medical and integrating Cardea Catheter Innovations, is a Minneapolis-based entity focused on the design, development, and manufacturing of complex catheter devices. The company serves critical medical fields including Structural Heart, Electrophysiology, and Neurovascular. Leveraging the extensive experience of its veteran team, NovelCath emphasizes research and development, alongside prototyping, to support early-stage medical device programs. Their vertically integrated facility is equipped with advanced technologies for catheter assembly and Nitinol processing, positioning them as a key player in the medical device supply chain.
How much funding has NovelCath raised?
NovelCath has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in NovelCath
PPP
Public-Private Partnership
What's next for NovelCath?
With a substantial capital infusion and a strategic investment, NovelCath is poised for accelerated growth and enhanced operational capabilities. This backing is expected to fuel further advancements in their R&D and manufacturing processes, potentially expanding their capacity to handle more complex projects and larger-scale production runs. The company's focus on interventional delivery systems for high-growth medical sectors suggests a strategic direction towards solidifying its market leadership and exploring new technological frontiers in device innovation.
See full NovelCath company page
